Personalised cancer follow-up: Risk stratification, needs assessment or both

British Journal of Cancer

Volumn 106, Issue 1, 2012, Pages 1-5

  Watson, E K ^a   Rose, P W ^b   Neal, R D ^c   Hulbert Williams, N ^d   Donnelly, P ^e   Hubbard, G ^f   Elliott, J ^g   Campbell, C ^h   Weller, D ^h   Wilkinson, C ^c  

^a OXFORD BROOKES UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BANGOR UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF CHESTER   (United Kingdom)

^e TORBAY HOSPITAL   (United Kingdom)

^f UNIVERSITY OF STIRLING   (United Kingdom)

^g MACMILLAN CANCER SUPPORT   (United Kingdom)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; TAMOXIFEN;

ANXIETY; ARTHRALGIA; AXILLARY LYMPH NODE; BRACHYTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; DEEP VEIN THROMBOSIS; DEPRESSION; EARLY MENOPAUSE; ERECTILE DYSFUNCTION; FATIGUE; FOLLOW UP; FRACTURE; HEALTH ECONOMICS; HORMONAL THERAPY; HOT FLUSH; HUMAN; LYMPH NODE DISSECTION; LYMPHEDEMA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOLOGY; REVIEW; RISK ASSESSMENT; SHOULDER PAIN; SLEEP DISORDER; URINE INCONTINENCE;

FOLLOW-UP STUDIES; HUMANS; INDIVIDUALIZED MEDICINE; NEEDS ASSESSMENT; NEOPLASMS; RESEARCH; RISK;

EID: 84855404879     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.535     Document Type: Review

References (21)

1. Calman KC, Royston G (1997) Personal paper: risk language and dialects. BMJ 315: 939-942 (Pubitemid 27425129)
2. Ewertz M, Jensen AB (2011) Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncologica 50: 187-193
3. Foster C, Wright D, Hill H, Hopkinson J, Roffe L (2009) Psychosocial implications of living 5 years or more following a cancer diagnosis: a systematic review of the research evidence. Eur J Cancer Care 18(3): 223-247
4. Ganz P (2009) Survivorship: adult cancer survivors. Prim Care Clin Office Pract 4(36): 721-741
5. Greenspan SL, Nelson JB, Trump DL, Resnick NM (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer. A randomized trial. Ann Intern Med 146: 416-424 (Pubitemid 351650576)
6. Harrison SE, Watson EK, Ward AM, Khan NF, Turner D, Adams E, Forman D, Roche MF, Rose PW (2011) Primary health and supportive care needs of long-term cancer survivors: a questionnaire survey. J Clin Oncol 29: 2091-2098
7. Holmes T, Rahe RH (1967) The social readjustment rating scale. J Psychom Res 11: 213-218
8. Irwig L, Bennetts A (1997) Quality of life after breast conservation or mastectomy: a systematic review. Aust NZ Surg 67: 750-754 (Pubitemid 27487902)
9. Jefford M, Karahalios E, Pollard A, Baravelli C, Carey M, Franklin J, Aranda S, Schofield P (2008) Survivorship issues following treatment completion-results from focus groups with Australian cancer survivors and health professionals. J Cancer Surviv 2: 20-23
10. Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utley M, Moller H (2009) Cancer prevalence in the UK: estimates for 2008. Br J Cancer 101: 541-547
11. Murphy BL, Thomson CS, Dodwell D, Shenoy H, Mikeljevic JS, Forman D, Horgan K (2007) Postoperative wound complications and systemic recurrence in breast cancer. Br J Cancer 97: 1211-1217 (Pubitemid 350035803)
12. National Cancer Survivorship Initiative (2010a) Vision. January 2010. http://www.ncsi.org.uk/wp-content/uploads/NCSI-Vision-Document.pdf (accessed May 2011)
13. National Cancer Survivorship Initiative (2010b) Priorities for research on cancer survivorship. A report from the NCSI Research Workstream. June 2010. http://www.ncsi.org.uk/wp-content/uploads/NCSI-Research-Priori-ties-Report.pdf (accessed May 2011)
14. NHS Information Centre (2011) National Mastectomy and Reconstruction Audit 2011. NHS Information Centre: Leeds, UK
15. Petrek JA, Senie RT, Peters M, Rosen PP (2001) Lymphoedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 92: 1369-1374
16. Renehan AG, Egger M, Saunders MP, O'Dwyer ST (2002) Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ 324: 813
17. Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, Palli D, del Roselli TM, Liberati A (2005) Cochrane Database Syst Rev 25(1): CD001768
18. Shahinian VB, Kuo YF, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2): 154-164 (Pubitemid 40096612)
19. Smith DP, King MT, Egger S, Berry MP, Stricker PD, Cozzi P, Ward J, O'Connell DL, Armstrong BK (2009) Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ 339: b4817
20. Wang TJ, Levy D, Benjamin EJ, Vasan RS (2003) The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening. Ann Int Med 138: 907-916
21. Wilson JMG, Junger G (1968) Principles and Practice of Screening for Disease. World Health Organisation: Geneva